Currently, we do not have any vacancies, but we are always interested to meet enthusiastic talent !


Mail your motivation letter, together with your CV in English to Marco de Boer (

Company profile

NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. The iTOP intracellular delivery technology is based on a combination of small molecule compounds which forces the uptake of large gulps of extracellular fluid (containing the bioactive molecules) by the cell (D’Astolfo et al. 2015, Cell 161: 674-690). Once inside, the vesicles release their content into the cytoplasm, where the bioactive molecules (like gene editing systems) can exert their therapeutic action.

The goal of NTrans Technologies is to further develop the iTOP transduction technology into a therapeutic platform for the treatment of (genetic) disorders and cancer.

Agency or sales calls are not appreciated

New therapies for the treatment of genetic diseases and cancer
Contact us